News & Updates

Show Multimedia Only

Monthly erenumab jabs promising for chronic migraine, medication overuse headaches

28 Sep 2024 by

Monthly injections of erenumab help induce and sustain remission of chronic migraine and medication overuse headaches, as shown in the phase IV INOVA study.

Monthly erenumab jabs promising for chronic migraine, medication overuse headaches

28 Sep 2024

Large UK study underpins role of COVID-19 vax in mental illness

27 Sep 2024 by

In a cohort study of over 18 million individuals with up to 2 years of follow-up, the incidences of most mental illnesses were markedly elevated following COVID-19 diagnosis compared with before or without COVID-19, particularly among the unvaccinated and before COVID-19 vaccines became available.

Large UK study underpins role of COVID-19 vax in mental illness

27 Sep 2024

Medical cannabinoids come with risks for paediatric use

25 Sep 2024

Cannabinoids for medical purposes in children and adolescents have been linked to increased risk of adverse events (AEs), according to the results of a meta-analysis.

Medical cannabinoids come with risks for paediatric use

25 Sep 2024

Rimegepant for long-term acute Tx of migraine cuts monthly attack days, shows no MOH signal

24 Sep 2024

In patients with ≥1 year’s history of migraine and ≥6 monthly migraine days (MMDs), acute treatment of migraine with rimegepant 75 mg up to once daily as needed for up to 52 weeks is associated with reduced MMDs, with no increase in monthly tablet utilization and no evidence of medication overuse headache (MOH), a post hoc analysis of an open-label safety study has shown.

Rimegepant for long-term acute Tx of migraine cuts monthly attack days, shows no MOH signal

24 Sep 2024

Poststroke seizures, epilepsy tied to increased dementia risk

23 Sep 2024

Stroke survivors with seizures or epilepsy are at greater risk of dementia, according to a retrospective study.

Poststroke seizures, epilepsy tied to increased dementia risk

23 Sep 2024

Rimegepant shows favourable safety and tolerability in long-term acute migraine treatment

20 Sep 2024

Rimegepant, taken for up to 1 year for acute treatment of migraine, is well tolerated with no signal of hepatotoxicity, a recent study has shown.

Rimegepant shows favourable safety and tolerability in long-term acute migraine treatment

20 Sep 2024

Study warns of increased PD risk among people with upper GI mucosal damage history

17 Sep 2024 by

A history of upper gastrointestinal (GI) mucosal damage, such as peptic ulcer disease and erosions, has been associated with subsequent incidence of Parkinson’s disease (PD) in a study.

Study warns of increased PD risk among people with upper GI mucosal damage history

17 Sep 2024

Brivaracetam benefits Asian adults with uncontrolled focal-onset seizures

13 Sep 2024 by

Adjunctive brivaracetam (BRV) reduces seizure frequency and improves response in Asian adults with uncontrolled focal-onset seizures (FOS), findings from the phase III therapeutic confirmatory EP0083 study suggest.

Brivaracetam benefits Asian adults with uncontrolled focal-onset seizures

13 Sep 2024

No link between COVID-19 vaccines and new-onset seizures

12 Sep 2024

Individuals who have been vaccinated against COVID-19 appear to have a risk of new-onset seizure that is similar to that observed among unvaccinated individuals, according to the results of a meta-analysis.

No link between COVID-19 vaccines and new-onset seizures

12 Sep 2024

Serum SFA levels linked to mild cognitive impairment

11 Sep 2024

Serum concentrations of saturated fatty acids (SFAs) appear to predict the development of mild cognitive impairment (MCI) in middle-aged and older adults, reports a study.

Serum SFA levels linked to mild cognitive impairment

11 Sep 2024

News & Updates

Filter by Specialty:

Specialty:

Monthly erenumab jabs promising for chronic migraine, medication overuse headaches

Monthly erenumab jabs promising for chronic migraine, medication overuse headaches

Large UK study underpins role of COVID-19 vax in mental illness

Large UK study underpins role of COVID-19 vax in mental illness

Medical cannabinoids come with risks for paediatric use

Medical cannabinoids come with risks for paediatric use

Rimegepant for long-term acute Tx of migraine cuts monthly attack days, shows no MOH signal

Rimegepant for long-term acute Tx of migraine cuts monthly attack days, shows no MOH signal

Poststroke seizures, epilepsy tied to increased dementia risk

Poststroke seizures, epilepsy tied to increased dementia risk

Rimegepant shows favourable safety and tolerability in long-term acute migraine treatment

Rimegepant shows favourable safety and tolerability in long-term acute migraine treatment

Study warns of increased PD risk among people with upper GI mucosal damage history

Study warns of increased PD risk among people with upper GI mucosal damage history

Brivaracetam benefits Asian adults with uncontrolled focal-onset seizures

Brivaracetam benefits Asian adults with uncontrolled focal-onset seizures

No link between COVID-19 vaccines and new-onset seizures

No link between COVID-19 vaccines and new-onset seizures

Serum SFA levels linked to mild cognitive impairment

Serum SFA levels linked to mild cognitive impairment